Long-Term Follow-Up Study for Uveal Melanoma and Eye Lesion Patients

In Plain English

This study is following people like you who participated in a previous Aura Biosciences trial for uveal melanoma (eye cancer) or indeterminate lesions (spots in the eye that doctors are watching). The researchers want to understand how well the treatment worked over many years and whether any side effects develop later on. You're not receiving any new treatment in this study—instead, doctors will simply collect information from your regular eye care and cancer check-up appointments over at least 5 years. This helps Aura Biosciences and the medical community learn what happens to patients long-term, which can help future patients with the same condition.

What This Trial Does

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

How It Works

This is a multi-center long-term observational Registry of subjects with Primary Indeterminate Lesions or Choroidal Melanoma. The Registry will initially be open to subjects who have previously participated in an Aura Biosciences bel-sar sponsored clinical trial for their primary Choroidal Melanoma or Indeterminate Lesions. All subjects will be followed for a minimum of 5 years (including time enrolled in an Aura sponsored clinical trial), until withdrawal of consent, or until death whichever comes first. No interventions will be required as part of the Registry. Data collection will be based on IL or CM information anticipated to be available based on the standard of care for subjects with CM or IL.

Who Can Join